127
Views
4
CrossRef citations to date
0
Altmetric
REVIEW

Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis

, , ORCID Icon, , , ORCID Icon & show all
Pages 1665-1679 | Received 11 Jun 2022, Accepted 26 Oct 2022, Published online: 18 Nov 2022

References

  • Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. doi:10.3389/fped.2019.00246
  • Trivedi M, Denton E. Asthma in children and adults-what are the differences and what can they tell us about asthma? Front Pediatr. 2019;7:256. doi:10.3389/fped.2019.00256
  • Asthma GIf. Global; 2019. Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed November 2, 2022.
  • Pelaia C, Crimi C, Vatrella A, Tinello C, Terracciano R, Pelaia G. Molecular targets for biological therapies of severe asthma. Front Immunol. 2020;11:603312. doi:10.3389/fimmu.2020.603312
  • Ricciardolo FLM, Bertolini F, Carriero V. The role of dupilumab in severe asthma. Biomedicines. 2021;9(9):1096. doi:10.3390/biomedicines9091096
  • Eger K, Amelink M, Hashimoto S, Hekking PP, Longo C, Bel EH. Overuse of oral corticosteroids, underuse of inhaled corticosteroids, and implications for biologic therapy in asthma. Respiration. 2022;101(2):116–121. doi:10.1159/000518514
  • Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res. 2010;690(1–2):24–39. doi:10.1016/j.mrfmmm.2009.09.005
  • Esteban-Gorgojo I, Antolín-Amérigo D, Domínguez-Ortega J, Quirce S. Non-eosinophilic asthma: current perspectives. J Asthma Allergy. 2018;11:267–281. doi:10.2147/JAA.S153097
  • Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. doi:10.1186/s12931-020-01505-x
  • Ziegler SF. Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol. 2012;130(4):845–852. doi:10.1016/j.jaci.2012.07.010
  • Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015;75(1):68–78. doi:10.1016/j.cyto.2015.05.014
  • Li Y, Wang W, Lv Z, et al. Elevated expression of IL-33 and TSLP in the airways of human asthmatics in vivo: a potential biomarker of severe refractory disease. J Immunol. 2018;200(7):2253–2262. doi:10.4049/jimmunol.1701455
  • Corren J, Ambrose CS, Sałapa K, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J Allergy Clin Immunol Pract. 2021;9(12):4334–42.e6. doi:10.1016/j.jaip.2021.07.045
  • Parnes JR, Sullivan JT, Chen L, Dias C. Pharmacokinetics, safety, and tolerability of tezepelumab (AMG 157) in healthy and atopic dermatitis adult subjects. Clin Pharmacol Ther. 2019;106(2):441–449. doi:10.1002/cpt.1401
  • Corren J, Garcia Gil E, Griffiths JM, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021;126(2):187–193. doi:10.1016/j.anai.2020.10.008
  • Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299–1312. doi:10.1016/S2213-2600(21)00226-5
  • Emson C, Corren J, Sałapa K, Hellqvist Å, Parnes JR, Colice G. Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the phase 2b PATHWAY study. J Asthma Allergy. 2021;14:91–99. doi:10.2147/JAA.S288260
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
  • Rohatgi A. WebplotDigitizer (Version 4.6) {Computer software}; 2021. Available from: http://arohatgi.info/WebPlotDigitizer.2022. Accessed November 2, 2022.
  • Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
  • Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:Ed000142. doi:10.1002/14651858.ED000142
  • Study to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma (SOURCE). Available from: https://clinicaltrials.gov/ct2/show/NCT03406078. Accessed November 2, 2022.
  • Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975
  • Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716–1726. doi:10.1111/all.13850
  • Rogliani P, Calzetta L, Matera MG, et al. Severe Asthma and Biological Therapy: when, Which, and for Whom. Pulm Ther. 2020;6(1):47–66. doi:10.1007/s41030-019-00109-1
  • Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20(1):179. doi:10.1186/s12931-019-1138-3